4 completed, 4 recruiting, 3 not yet recruiting, 1 unknown. 12 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 4, Recruiting 4, Not yet recruiting 3, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Venous Thromboembolism (VTE): new trials by email Literature Review of Venous Thromboembolism (VTE) trials Research Report on Venous Thromboembolism (VTE)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP). Enoxaparin - Venous Thromboembolism (VTE) | Phase 3 | Not yet recruiting | Johns Hopkins All Children's Hospital | 802 | 2027-04-15 | 2026-05-26 |
| Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC) REGN7508, REGN9933, Placebo - Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1908 | 2026-09-07 | 2026-09-29 |
| Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers REGN7508, Apixaban - Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1600 | 2026-08-26 | 2026-10-21 |
| Design and Rationale of the COLT Study Colchicine 0.5 MG Oral Tablet, Placebo - Venous Thrombosis Deep (Limbs), Post-thrombotic Syndrome | Phase 3 | Not yet recruiting | Azienda Sanitaria Locale ASL 6, Livorno | 940 | 2026-06-01 | 2026-02-25 |
| Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention rivaroxaban and ASA, Low-molecular weight heparin, Fondaparinux - Hip Fracture Surgery, Cardiovascular Prevention | Phase 3 | Not yet recruiting | McMaster University | 100 | 2025-12-01 | 2025-11-14 |
| Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis Low-dose low-molecular-weight heparin - Venous Thromboembolism (VTE), Postpartum | Phase 3 | Recruiting | Marc Blondon | 9200 | 2025-10-15 | 2026-10-06 |
| REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults REGN7508, Apixaban, Enoxaparin - Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 2000 | 2025-06-25 | 2026-10-08 |
| Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial Anti-Xa Guided Dosing of Low Molecular Weight Heparin, Standard of Care Dosing - Venous Thromboembolism (VTE), Trauma Related Injuries | Phase 2 / Phase 3 | Unknown | Alexandre Tran | 150 | 2025-01-01 | 2024-10-28 |
| Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin Sodium enoxaparin, Dimolegin, Dimolegin placebo - Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee | Phase 3 | Completed | Avexima Diol LLC | 215 | 2024-07-22 | 2026-01-16 |
| Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) Edoxaban, Standard of Care - Venous Thromboembolism (VTE), Pulmonary Embolism | Phase 3 | Completed | Daiichi Sankyo | 290 | 2017-03-27 | 2025-02-28 |
| Cancer Venous Thromboembolism (VTE) Edoxaban, Dalteparin, Low molecular weight heparin - Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT) | Phase 3 | Completed | Daiichi Sankyo | 1046 | 2015-07-16 | 2019-03-06 |
| Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) Betrixaban, Enoxaparin - Venous Thromboembolism (VTE) | Phase 3 | Completed | Portola Pharmaceuticals | 7513 | 2012-03-01 | 2023-08-07 |
Venous Thromboembolism (12) · Venous Thrombosis (4) · Pulmonary Embolism (3) · Neoplasms (2) · Critical Illness (1) · Inflammation (1) · Postthrombotic Syndrome (1) · Thrombosis (1) · Venous Insufficiency (1) · Wounds and Injuries (1)
Cardiovascular Diseases (12) · Embolism and Thrombosis (12) · Thromboembolism (12) · Vascular Diseases (12) · Thrombosis (4) · Embolism (3) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Disease Attributes (1)
Enoxaparin (6) · apixaban (3) · Dalteparin (2) · Fondaparinux (2) · Heparin, Low-Molecular-Weight (2) · edoxaban (2) · (+-)-(1'R*,2'S*,6'R*)-(2-hydroxy-4,6-dimethoxyphenyl)(3'-methyl-2'-(3''-methylbut-2''-enyl)-6-phenylcyclohex-3'-enyl)methanone (1) · Aspirin (1) · Colchicine (1) · Heparin (1) · N(4)-oleylcytosine arabinoside (1) · Rivaroxaban (1) · Standard of Care (1) · Tablets (1) · Tinzaparin (1)
Regeneron Pharmaceuticals (3) · Daiichi Sankyo (2) · Alexandre Tran (1) · Avexima Diol LLC (1) · Azienda Sanitaria Locale ASL 6, Livorno (1) · Johns Hopkins All Children's Hospital (1) · Marc Blondon (1) · McMaster University (1) · Portola Pharmaceuticals (1)
United States (6) · Bulgaria (4) · Hungary (4) · Romania (4) · Canada (3) · France (3) · Italy (3) · Russia (3) · Argentina (2) · Belgium (2) · Brazil (2) · Chile (2) · Croatia (2) · Czechia (2) · Denmark (2)
Alexandre Tran, MD, MSc, FRCSC (1) · Anthony Sochet, MD, MSc (1) · Federico Germini, Doctor of Medicine (1) · Marc Carrier, MD, MSc, FRCPC (1)
PMID 24576517, PMID 26271200, PMID 27232649, PMID 27881569, PMID 28617144, PMID 28625365, PMID 28698258, PMID 28762617, PMID 28840662, PMID 28905172, PMID 29188425, PMID 29212126, PMID 29231094, PMID 30252149, PMID 30419597, PMID 30778649, PMID 31215264, PMID 31249989, PMID 32657973, PMID 36566304, PMID 37855029, PMID 41223938
2025 (2), 2014 (1), 2016 (1)